EC-T新辅助化疗方案治疗Ⅱ、Ⅲ期乳腺癌的近期疗效

Short-term efficacy of EC-T neoadjuvant chemotherapy for stage Ⅱ-Ⅲ breast cancer

目的观察EC-T新辅助化疗方案治疗Ⅱ、Ⅲ期乳腺癌患者的近期疗效。方法Ⅱ、Ⅲ期乳腺癌患者80例随机均分为两组:观察组采用EC-T新辅助化疗方案(表柔比星+环磷酰胺序贯多西他赛)治疗,对照组采用TEC方案(多西他赛+表柔比星+环磷酰胺)治疗。比较两组近期疗效和药物不良反应发生情况。结果观察组治疗后完全缓解和部分缓解的患者共29例,临床治疗总有效率为72.5%,高于对照组的52.5%(P<0.05);观察组32.5%的患者白细胞计数低于2.0×109/L,低于对照组的72.5%(P<0.05)。结论Ⅱ、Ⅲ期乳腺癌患者采用EC-T新辅助化疗方案治疗的近期疗效优于TEC方案,且骨髓抑制作用较轻。

Objective To observe the short-term efficacy of EC-T neoadjuvant chemotherapy regimen in treating the patients with stageⅡ-Ⅲ breast cancer.Methods Eighty patients with stageⅡ-Ⅲ breast cancer were randomly divided into two groups and treated with EC-T neoadjuvant chemotherapy regimen(group A,40 cases)or with TEC regimen(group B,40 cases).The short-term efficacy and adverse responses were compared between two groups.Results There were 29 patients with complete response or partial response in group A.The overall effectiveness rate was 72.5%in group A,which was higher than 52.5%in group B(P<0.05).The percentage of the patients with leukocytes less than 2.0×109/L was 32.5%in group A,which was lower than 72.5%in group B(P<0.05).Conclusion Compared to TEC regimen for the treatment of stageⅡ-Ⅲbreast cancer,the short-term efficacy of EC-T neoadjuvant chemotherapy regimen is better with mild myelosuppressive effect.